Apparently Affitech also has disgruntled shareholders:
29-12-2009 - 23:10
Affitech Issues Update on Litigation
Release No 38/2009
Affitech Issues Update on Litigation
Copenhagen and Oslo, December 29th, 2009
Affitech A/S, (Nasdaq OMX: AFFI), the antibody medicines company, today
announced that the ongoing litigation with a minority group of shareholders has
been resumed in the Lyngby court, as requested by Affitech, following an action
from the plaintiffs for an early ruling against the Company. The Company
expects the court to now consider Affitech's response to the plaintiffs'
claims. As stated previously in the Company's June 30th prospectus document,
Affitech continues to believe that there is no legal basis for the objections
filed in the minority shareholders' writ and the Company intends to defend its
position vigorously.
For more information please contact:
Affitech:
Robert F Burns, PhD
CEO
Tel # +45 50 99 76 42
About Affitech
Affitech AS is a publically traded (Nasdaq OMX Copenhagen exchange) human
therapeutic antibody company headquartered in Copenhagen, Denmark with R&D
facilities in Oslo, Norway. The company utilizes a range of proprietary
antibody technologies for the discovery of fully human antibodies for
application in oncology, inflammation and other disease areas. CBAS™ (Cell
Based Antibody Selection) is Affitech's premier discovery engine for the
isolation of lead antibodies to cell surface molecules in situ. Several of the
Company's proprietary product candidates were generated by CBAS™. Further
information is available at www.affitech.com.
Market Data 
Markets 
AI
